The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia.
about
Anti-CD19 Monoclonal Antibodies: a New Approach to Lymphoma TherapyMonoclonal antibodies in acute lymphoblastic leukemiaTargeting CD19 in B-cell lymphoma: emerging role of SAR3419Recent advances and novel treatment paradigms in acute lymphocytic leukemiaThe future of patient-derived tumor xenografts in cancer treatment.Targeting the 5T4 oncofetal glycoprotein with an antibody drug conjugate (A1mcMMAF) improves survival in patient-derived xenograft models of acute lymphoblastic leukemia.Stability of gene expression and epigenetic profiles highlights the utility of patient-derived paediatric acute lymphoblastic leukaemia xenografts for investigating molecular mechanisms of drug resistance.Molecular profiling of childhood cancer: Biomarkers and novel therapiesDrug discovery in paediatric oncology: roadblocks to progress.Ocular Adverse Events Associated with Antibody-Drug Conjugates in Human Clinical TrialsAntibody therapy for pediatric leukemia.The evolution of clinical trials for infant acute lymphoblastic leukemia.Antibody-based therapies in B-cell lineage acute lymphoblastic leukaemia.Current status of antibody therapy in ALL.Modern immunotherapy of adult B-lineage acute lymphoblastic leukemia with monoclonal antibodies and chimeric antigen receptor modified T cells.Novel approaches to pediatric leukemia treatment.Novel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemiaImmunotherapy approaches to treat adult acute lymphoblastic leukemia.Novel Therapeutic Strategies in Acute Lymphoblastic Leukemia.The development of targeted new agents to improve the outcome for children with leukemia.Acute lymphoblastic leukemia: a comprehensive review and 2017 updateA Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia.Efficacy studies of an antibody-drug conjugate PSMA-ADC in patient-derived prostate cancer xenografts.Emerging role of immunotherapy in precursor B-cell acute lymphoblastic leukemia.Bioluminescence Imaging Enhances Analysis of Drug Responses in a Patient-Derived Xenograft Model of Pediatric ALL.Xenograft-directed personalized therapy for a patient with post-transplant relapse of ALL.
P2860
Q26775363-25235767-B2D0-4FDE-8261-22FE14449757Q27022540-13374DE7-F843-4DBB-915D-33A044B339DEQ27027562-C33A7274-9030-4C0D-BA0E-7992E8A27F37Q28078076-59D5CB17-97F2-44CD-9BF8-97A41F741B9DQ33361578-E1B38626-62EB-4E38-A9AE-C4F128F71C86Q33746736-6BABCA6B-D7C0-41CE-AD52-2021360BA58AQ33755247-EC5B9656-A546-4758-9F1E-B54097F65935Q36250783-BC8F5564-91D0-43AE-9A25-A464B5A1C91BQ36262295-9C00ADFE-F70C-4ECC-88EA-9C26568D1054Q36366709-BE13EADC-F472-45C5-A8F4-F2CEE18B6C17Q37725578-1C270F03-2637-461F-8F3D-E14E692E8A29Q37730023-14DF4A49-E318-4129-9A3E-3D3390E7DFA4Q38224988-84998178-621B-4290-8E54-1E6F9EA65EB3Q38266338-92E513CD-34F3-4C80-A95A-15DE489702CDQ38312596-742110F3-19E4-4EF1-8533-F46D1F200E60Q38500371-EDCE5B2F-19F9-4BA6-B6CA-EC7E42513762Q38640263-0E7A7320-6FC0-4EFB-A66E-7B5915CC9077Q38787405-E98C7A3F-4892-4275-84FE-26F8E1CDB152Q38813978-8DA0CC94-07EE-4DE3-BC78-6889542A00B9Q38964974-F7F0EEF6-435D-4B85-BEAE-B175F88147E0Q39406969-2509FFF0-E564-4860-90E3-CB0EF89F73B0Q40971388-79991C4F-2F8D-4F6B-9FB8-14687121FB6FQ42467386-7EA9B050-E9C7-4645-A49B-D102132D3F6CQ48192887-B2B307A3-7E8A-4135-8AD9-BEA8DF19A1A4Q50209854-326D37FC-FDC3-4F76-AA95-961C0CA40DDCQ53100287-691568C3-6F93-4087-BD55-72CFB431D48B
P2860
The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
The anti-CD19 antibody-drug co ...... acute lymphoblastic leukemia.
@ast
The anti-CD19 antibody-drug co ...... acute lymphoblastic leukemia.
@en
type
label
The anti-CD19 antibody-drug co ...... acute lymphoblastic leukemia.
@ast
The anti-CD19 antibody-drug co ...... acute lymphoblastic leukemia.
@en
prefLabel
The anti-CD19 antibody-drug co ...... acute lymphoblastic leukemia.
@ast
The anti-CD19 antibody-drug co ...... acute lymphoblastic leukemia.
@en
P2093
P2860
P1476
The anti-CD19 antibody-drug co ...... c acute lymphoblastic leukemia
@en
P2093
Barbara Szymanska
Hernan Carol
Ingrid Boehm
Kathryn Evans
Peter J Houghton
P2860
P304
P356
10.1158/1078-0432.CCR-12-3613
P407
P577
2013-02-20T00:00:00Z